News | July 23, 2021
Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
This oxygen is being provided free-of-cost to several state governments across the country to bring immediate relief to over 1 lakh patients on a daily basis
Essential medicines were made available to more than 150 countries around the world during the pandemic
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
Subscribe To Our Newsletter & Stay Updated
